Ziltivekimab for reducing cardiovascular risk in patients with acute myocardial infarction

Ziltivekimab is currently in development for the reduction of cardiovascular risk in patients with acute myocardial infarction. A myocardial infarction (heart attack) happens when blood flow to the heart is suddenly blocked, usually by a blood clot. This can seriously damage the heart and can be life threatening. Even with current treatments, heart problems like heart failure still led to many deaths, and so there is a need for effective treatments.